Home » Stocks » INO

Inovio Pharmaceuticals, Inc. (INO)

Stock Price: $11.10 USD -0.39 (-3.39%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $11.36 +0.26 (2.34%) Feb 26, 7:59 PM
Market Cap 2.27B
Revenue (ttm) 2.11M
Net Income (ttm) -179.73M
Shares Out 165.36M
EPS (ttm) -1.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $11.10
Previous Close $11.49
Change ($) -0.39
Change (%) -3.39%
Day's Open 11.56
Day's Range 10.85 - 11.85
Day's Volume 12,264,315
52-Week Range 3.83 - 33.79

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Benzinga - 1 day ago

On Monday, March 01, Inovio Pharmaceuticals (NASDAQ:INO) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.

Zacks Investment Research - 1 day ago

Inovio (INO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Benzinga - 3 days ago

Qiagen NV (NYSE: QGEN) and Inovio Pharmaceuticals Inc (NASDAQ: INO) expanded their partnership with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic pro...

Other stocks mentioned: QGEN
PRNewsWire - 3 days ago

PLYMOUTH MEETING, Pa. and GERMANTOWN, Md. and HILDEN, Germany, Feb. 24, 2021 /PRNewswire/ -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and INOVIO Pharmaceuticals (NASDAQ: INO) today a...

Zacks Investment Research - 5 days ago

Inovio (INO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 5 days ago

On Inovio's (INO) fourth-quarter earnings call, investor focus will be on updates on the company's progress with the development of its COVID-19 vaccine candidate, INO-4800.

The Motley Fool - 6 days ago

This straggler in the vaccine race is still facing some struggles -- but there are a couple of bright spots.

Zacks Investment Research - 1 week ago

Inovio Pharmaceuticals (INO) closed the most recent trading day at $13.84, moving -0.93% from the previous trading session.

The Motley Fool - 1 week ago

The choice isn't easy, but simplicity may be the answer.

Other stocks mentioned: VXRT
Benzinga - 2 weeks ago

Shares of coronavirus vaccine developer Inovio Pharmaceuticals Inc (NASDAQ: INO) were surging Friday after a vote of confidence from the Street.  Bullish Analyst, Fund Stake Prop Up Stock: Opp...

The Motley Fool - 2 weeks ago

An analyst is really bullish about the biotech stock.

Benzinga - 2 weeks ago

One of the most common questions traders have about stocks is “Why Is It Moving?”. That's why Benzinga created the Why Is It Moving, or WIIM, feature in Benzinga Pro.

Other stocks mentioned: DIS, FSR, HYLN
The Motley Fool - 2 weeks ago

Once a leader in the COVID-19 vaccine race, does this biotech have what it takes to deliver market-shattering returns?

The Motley Fool - 2 weeks ago

Reddit investors are sure hyped up about shares of this biotech underdog. Should you be as well?

Invezz - 3 weeks ago

In less than several weeks, Inovio Pharmaceuticals (NASDAQ: INO) shares have advanced from $8.8 to $19, and the current price stands around $15. Inovio Pharmaceuticals has signed an agreement ...

Benzinga - 3 weeks ago

Other stocks mentioned: BB, BNGO
The Motley Fool - 3 weeks ago

Probably not, if you're investing for the long term.

Other stocks mentioned: ARCT, VXRT
The Motley Fool - 3 weeks ago

Pessimists have piled into these companies, but that doesn't seem to be fazing millennial investors one bit.

Other stocks mentioned: AMC, GME, AAL, BLNK, NKLA, SPCE, TLRY, TXMD, WKHS
Seeking Alpha - 4 weeks ago

INO is one of the most highly shorted biotechs and among the top 25 stocks in terms of short interest listed on the NASDAQ/AMEX/NYSE. INO has recently raised funds and is planning to start a p...

The Motley Fool - 4 weeks ago

None of them outperformed the cryptocurrency in 2020, but that could change this year.

Other stocks mentioned: ARKK, HEXO
InvestorPlace - 1 month ago

Some of the best cheap stocks for 2021 include chipmakers like UMC stock and pharmaceuticals in the COVID-19 vaccine race such as INO stock. The post 7 Great Cheap Stocks To Buy For Solid Grow...

Other stocks mentioned: AMRS, CLNE, GNMK, HIMX, STKL, UMC
PRNewsWire - 1 month ago

PLYMOUTH MEETING, Pa., Jan. 25, 2021 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat...

The Motley Fool - 1 month ago

All four biotechs announced the pricing of stock offerings.

Other stocks mentioned: CTMX, EDIT
Market Watch - 1 month ago

Shares of Inovio Pharmaceuticals Inc. were down 5.1% in premarket trading on Thursday, the day after the company announced a public offering of 17,700,000 shares at $8.50 per share. The stock ...

PRNewsWire - 1 month ago

PLYMOUTH MEETING, Pa., Jan. 20, 2021 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat...

PRNewsWire - 1 month ago

PLYMOUTH MEETING, Pa., Jan. 20, 2021 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat...

The Motley Fool - 1 month ago

The biotech company's COVID-19 vaccine candidate may not be near the finish line, but that doesn't mean investors should count it out just yet.

Seeking Alpha - 1 month ago

Gracell Biotech completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a dea...

Other stocks mentioned: ARGX, EYPT, GILD, GRCL, LLY, PRTK, ZLAB
PRNewsWire - 1 month ago

PLYMOUTH MEETING, Pa., Jan. 6, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from...

InvestorPlace - 1 month ago

When will INO stock finally turn a corner? That's a question on some investor's minds, and recent data suggests a turnaround might be afoot.

Benzinga - 1 month ago

Shares of Inovio Pharmaceuticals Inc (NASDAQ: INO), which is developing a DNA vaccine against the novel coronavirus, were advancing Monday. What Happened: Plymouth Meeting, Pennsylvania-based ...

Market Watch - 1 month ago

Shares of Inovio Pharmaceuticals Inc. were up 4.5% in premarket trading on Monday after the company announced a licensing deal with Advaccine Biopharmaceuticals Suzhou Co. Ltd. for its COVID-1...

The Motley Fool - 1 month ago

Investors in fast-moving biotechs made out like bandits.

Other stocks mentioned: CODX, FLGT, MRNA, ARCT
The Motley Fool - 1 month ago

This coronavirus vaccine drugmaker has already made many of its early investors rich, but its valuation is still dirt cheap.

The Motley Fool - 1 month ago

Analysts have very different takes on the early-stage results for the company's COVID-19 vaccine candidate.

Zacks Investment Research - 2 months ago

We discuss six biotech/drug stocks, NVAX, VXRT, MRNA, TBIO, INO and BNTX that have more than doubled in 2020 on the back of their progress in coronavirus vaccine development.

Other stocks mentioned: BNTX, MRNA, NVAX, TBIO, VXRT
Benzinga - 2 months ago

Inovio Pharmaceuticals Inc (NASDAQ: INO) shares were trading higher Thursday after the company released positive Phase 1 data on to its COVID-19 DNA vaccine candidate. What Happened: On Wednes...

PRNewsWire - 2 months ago

PLYMOUTH MEETING, Pa., Dec. 24, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people fro...

The Motley Fool - 2 months ago

These stocks could shine next year, assuming they don't stumble beforehand.

Other stocks mentioned: IIPR, TDOC
Zacks Investment Research - 2 months ago

Investors need to pay close attention to Inovio Pharmaceuticals (INO) stock based on the movements in the options market lately.

The Motley Fool - 2 months ago

The biotech is trailing the leaders.

The Motley Fool - 2 months ago

Investors favored coronavirus vaccine work, late-stage trial victories, and genetic sequencing.

Other stocks mentioned: MCRB, NVAX, PFE, TWST
PRNewsWire - 2 months ago

PLYMOUTH MEETING, Pa., Dec. 9, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from...

Market Watch - 2 months ago

Shares of Inovio Pharmaceuticals Inc. gained 0.6% in premarket trading on Monday after the company said it started dosing participants in a Phase 2 clinical trial for its experimental COVID-19...

The Motley Fool - 2 months ago

The company taps another partner to help make its coronavirus vaccine when, and if, it's approved.

Benzinga - 2 months ago

Inovio Pharmaceuticals Inc (NASDAQ: INO), which is developing a DNA vaccine against SARS-CoV-2, issued an update on its vaccine program Thursday, sending the stock higher.  What Happened: The ...

InvestorPlace - 2 months ago

While INO stock has boasted a banner year, Inovio appears no closer to a Covid-19 vaccine than any of the other 150 contenders. The post Just Say No to Inovio Pharmaceuticals Stock appeared fi...

InvestorPlace - 2 months ago

Now that companies such as Pfizer, Moderna and AstraZeneca have emerged with viable vaccines against Covid-19, the hype around many pharmaceutical stocks is fading. Here are four stocks invest...

Other stocks mentioned: ABBV, NVAX, REGN
The Motley Fool - 2 months ago

A potential coronavirus vaccine isn't the only promising pipeline candidate for this small-cap biotech.

InvestorPlace - 2 months ago

If you're thinking that INO stock is just a wager on a Covid-19 vaccine candidate, think again. Inovio's pipeline is robust and diverse.

About INO

Inovio Pharmaceuticals, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells and facilitate cross-strain protection against unmatched and matched pathogens. The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated pre... [Read more...]

Industry
Biotechnology
IPO Date
Feb 12, 1998
CEO
Jong Kim
Employees
190
Stock Exchange
NASDAQ
Ticker Symbol
INO
Full Company Profile

Financial Performance

In 2019, INO's revenue was $4.11 million, a decrease of -86.51% compared to the previous year's $30.48 million. Losses were -$119.36 million, 23.1% more than in 2018.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for INO stock is "Hold." The 12-month stock price forecast is 15.13, which is an increase of 36.31% from the latest price.

Price Target
$15.13
(36.31% upside)
Analyst Consensus: Hold